Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Advanced Thyroid Cancer
NCT00095836Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2003
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in thyroid cancer, sponsored by Massachusetts General Hospital. Primary endpoint: Objective Tumor Response Rate at 1 year. Started Mar 2003; status: completed.
02
Drugs
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT00095836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095836.